179 related articles for article (PubMed ID: 16503874)
1. Matrix metalloproteinases: a potential therapeutic target in atherosclerosis.
Rouis M
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):541-8. PubMed ID: 16503874
[TBL] [Abstract][Full Text] [Related]
2. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
[TBL] [Abstract][Full Text] [Related]
3. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes.
Newby AC; George SJ; Ismail Y; Johnson JL; Sala-Newby GB; Thomas AC
Thromb Haemost; 2009 Jun; 101(6):1006-11. PubMed ID: 19492140
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability.
Johnson JL
Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):265-82. PubMed ID: 17338671
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases and atherosclerosis.
Watanabe N; Ikeda U
Curr Atheroscler Rep; 2004 Mar; 6(2):112-20. PubMed ID: 15023295
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
George SJ
Expert Opin Investig Drugs; 2000 May; 9(5):993-1007. PubMed ID: 11060722
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the Involvement of Matrix-Degrading Metalloproteinases (MMPs) in Atherosclerosis.
Brown BA; Williams H; George SJ
Prog Mol Biol Transl Sci; 2017; 147():197-237. PubMed ID: 28413029
[TBL] [Abstract][Full Text] [Related]
8. Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers.
Skjøt-Arkil H; Barascuk N; Register T; Karsdal MA
Assay Drug Dev Technol; 2010 Oct; 8(5):542-52. PubMed ID: 20662734
[TBL] [Abstract][Full Text] [Related]
9. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability.
Ruddy JM; Ikonomidis JS; Jones JA
J Vasc Res; 2016; 53(1-2):1-16. PubMed ID: 27327039
[TBL] [Abstract][Full Text] [Related]
10. Do metalloproteinases destabilize vulnerable atherosclerotic plaques?
Newby AC
Curr Opin Lipidol; 2006 Oct; 17(5):556-61. PubMed ID: 16960505
[TBL] [Abstract][Full Text] [Related]
11. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture.
Shah PK; Falk E; Badimon JJ; Fernandez-Ortiz A; Mailhac A; Villareal-Levy G; Fallon JT; Regnstrom J; Fuster V
Circulation; 1995 Sep; 92(6):1565-9. PubMed ID: 7664441
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells.
Bellosta S; Baetta R; Canavesi M; Comparato C; Granata A; Monetti M; Cairoli F; Eberini I; Puglisi L; Corsini A
Pharmacol Res; 2007 Aug; 56(2):160-7. PubMed ID: 17582780
[TBL] [Abstract][Full Text] [Related]
13. Impact of matrix metalloproteinases on atherosclerosis.
Lin J; Kakkar V; Lu X
Curr Drug Targets; 2014 Apr; 15(4):442-53. PubMed ID: 24517161
[TBL] [Abstract][Full Text] [Related]
14. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization.
Cevik C; Otahbachi M; Nugent K; Warangkana C; Meyerrose G
J Cardiovasc Med (Hagerstown); 2008 Dec; 9(12):1274-8. PubMed ID: 19001938
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting extracellular matrix metalloproteinase inducer maybe beneficial for diminishing the atherosclerotic plaque instability.
Xie S; Nie R; Wang J
J Postgrad Med; 2009; 55(4):284-6. PubMed ID: 20083879
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease.
Bench TJ; Jeremias A; Brown DL
Pharmacol Res; 2011 Dec; 64(6):561-6. PubMed ID: 21624471
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases and atherogenesis in dependence of age.
Kunz J
Gerontology; 2007; 53(2):63-73. PubMed ID: 17047333
[TBL] [Abstract][Full Text] [Related]
19. [Metalloproteinases: therapeutic target in atherosclerosis].
Jguirim-Souissi I; Jelassi A; Najah M; Rouis M; Slimane MN
Tunis Med; 2008 May; 86(5):490-6. PubMed ID: 19469306
[TBL] [Abstract][Full Text] [Related]
20. Proteinases and plaque rupture: unblocking the road to translation.
Newby AC
Curr Opin Lipidol; 2014 Oct; 25(5):358-66. PubMed ID: 25089553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
